Symposium
Symposium Highlights
Based on the scientific scope of the meeting, the following thematic sessions are planned:
Session 1: Tumor initiation & Prevention
Late stage cancers are frequently lethal, particularly if metastatic. This session therefore focuses on the early stages of the oncogenic process, to understand the mechanisms underlying its emergence and investigate their translation into actionable strategies for primary prevention and early detection.
Session 2: Tumor progression & Oncogenesis
This session explores the intrinsic mechanisms that dictate tumor cell identity, phenotypic evolution, and trajectory throughout disease progression. Moving away from external environmental factors, the focus centers on the cancer cell's internal dynamics, its capacity to navigate between different biological states, and its ability to sustain hierarchies of persistence.
Session 3: Microenvironment & Tumoral Heterogeneity
Tumor development and progression are orchestrated by both tumor cell-intrinsic alterations and dynamic interactions with the surrounding microenvironment. Tumor cells themselves also constitute a highly heterogeneous population, displaying distinct molecular and functional states. The reciprocal influence of microenvironmental factors and tumor heterogeneity shape disease progression and therapeutic responses. Dissecting these interactions is therefore essential to identify new actionable vulnerabilities and develop more effective therapeutic strategies.
Session 4: Immunology, Inflammation & immunotherapy
This session will showcase how basic mechanistic insights gained over recent years on immune response and inflammation has led to the development of innovative therapies targeting the immune system beyond approved checkpoint inhibitors. Integrating innate and adpative signals, immunotherapies in development open avenues for multi-modal activation of anti-tumor immune response, towards improved clinical response and patient survival.
Session 5: Resistance & Therapy
Therapeutic resistance represents a major obstacle to the long-term efficacy of cancer treatments, and constututes the leading cause of treatment failure. Overcoming this challenge requires a deeper understanding of the complex and dynamic mechanisms underlying tumor adaptation and resistance, paving the way for the development of innovative therapeutic strategies. This session will explore the contribution of metabolic reprogramming and cancer cell plasticity to intratumoral heterogeneity, metastatic progression and therapy resistance. It will also highlight emerging advances on the drivers of response to immunotherapies, and examine how can these might inform novel immunotherapy combinations for patients with cancer.